Cellular therapies in rheumatic and musculoskeletal diseases
A substantial proportion of patients diagnosed with rheumatologic and musculoskeletal diseases (RMDs) exhibit resistance to conventional therapies or experience recurrent symptoms. These diseases, which include autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and systemic lupus...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Journal of Translational Autoimmunity |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589909024000340 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583107152183296 |
|---|---|
| author | Pedro Franco-Fuquen Juana Figueroa-Aguirre David A. Martínez Eider F. Moreno-Cortes Juan E. Garcia-Robledo Fabio Vargas-Cely Daniela A. Castro-Martínez Mustafa Almaini Januario E. Castro |
| author_facet | Pedro Franco-Fuquen Juana Figueroa-Aguirre David A. Martínez Eider F. Moreno-Cortes Juan E. Garcia-Robledo Fabio Vargas-Cely Daniela A. Castro-Martínez Mustafa Almaini Januario E. Castro |
| author_sort | Pedro Franco-Fuquen |
| collection | DOAJ |
| description | A substantial proportion of patients diagnosed with rheumatologic and musculoskeletal diseases (RMDs) exhibit resistance to conventional therapies or experience recurrent symptoms. These diseases, which include autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, are marked by the presence of autoreactive B cells that play a critical role in their pathogenesis. The persistence of these autoreactive B cells within lymphatic organs and inflamed tissues impairs the effectiveness of B-cell-depleting monoclonal antibodies like rituximab.A promising therapeutic approach involves using T cells genetically engineered to express chimeric antigen receptors (CARs) that target specific antigens. This strategy has demonstrated efficacy in treating B-cell malignancies by achieving long-term depletion of malignant and normal B cells. Preliminary data from patients with RMDs, particularly those with lupus erythematosus and dermatomyositis, suggest that CAR T-cells targeting CD19 can induce rapid and sustained depletion of circulating B cells, leading to complete clinical and serological responses in cases that were previously unresponsive to conventional therapies.This review will provide an overview of the current state of preclinical and clinical studies on the use of CAR T-cells and other cellular therapies for RMDs. Additionally, it will explore potential future applications of these innovative treatment modalities for managing patients with refractory and recurrent manifestations of these diseases. |
| format | Article |
| id | doaj-art-9c73e22170f84f70bda3258a2354c871 |
| institution | Kabale University |
| issn | 2589-9090 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Translational Autoimmunity |
| spelling | doaj-art-9c73e22170f84f70bda3258a2354c8712025-01-29T05:01:39ZengElsevierJournal of Translational Autoimmunity2589-90902025-06-0110100264Cellular therapies in rheumatic and musculoskeletal diseasesPedro Franco-Fuquen0Juana Figueroa-Aguirre1David A. Martínez2Eider F. Moreno-Cortes3Juan E. Garcia-Robledo4Fabio Vargas-Cely5Daniela A. Castro-Martínez6Mustafa Almaini7Januario E. Castro8Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USADivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USA; Corresponding author. 6161 E Mayo Blvd, Phoenix, AZ, 85014, USA.Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USADivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USADivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USADivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USAStanford University, Stanford, CA, USARheumatology, Allergy & Clinical Immunology Division, Mafraq Hospital, United Arab EmiratesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USA; Corresponding author. 6161 E Mayo Blvd, Phoenix, AZ, 85014, USA.A substantial proportion of patients diagnosed with rheumatologic and musculoskeletal diseases (RMDs) exhibit resistance to conventional therapies or experience recurrent symptoms. These diseases, which include autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, are marked by the presence of autoreactive B cells that play a critical role in their pathogenesis. The persistence of these autoreactive B cells within lymphatic organs and inflamed tissues impairs the effectiveness of B-cell-depleting monoclonal antibodies like rituximab.A promising therapeutic approach involves using T cells genetically engineered to express chimeric antigen receptors (CARs) that target specific antigens. This strategy has demonstrated efficacy in treating B-cell malignancies by achieving long-term depletion of malignant and normal B cells. Preliminary data from patients with RMDs, particularly those with lupus erythematosus and dermatomyositis, suggest that CAR T-cells targeting CD19 can induce rapid and sustained depletion of circulating B cells, leading to complete clinical and serological responses in cases that were previously unresponsive to conventional therapies.This review will provide an overview of the current state of preclinical and clinical studies on the use of CAR T-cells and other cellular therapies for RMDs. Additionally, it will explore potential future applications of these innovative treatment modalities for managing patients with refractory and recurrent manifestations of these diseases.http://www.sciencedirect.com/science/article/pii/S2589909024000340Adoptive immunotherapyChimeric antigen receptorCell- and tissue-based therapyAutoimmune diseaseRheumatic and musculoskeletal disease |
| spellingShingle | Pedro Franco-Fuquen Juana Figueroa-Aguirre David A. Martínez Eider F. Moreno-Cortes Juan E. Garcia-Robledo Fabio Vargas-Cely Daniela A. Castro-Martínez Mustafa Almaini Januario E. Castro Cellular therapies in rheumatic and musculoskeletal diseases Journal of Translational Autoimmunity Adoptive immunotherapy Chimeric antigen receptor Cell- and tissue-based therapy Autoimmune disease Rheumatic and musculoskeletal disease |
| title | Cellular therapies in rheumatic and musculoskeletal diseases |
| title_full | Cellular therapies in rheumatic and musculoskeletal diseases |
| title_fullStr | Cellular therapies in rheumatic and musculoskeletal diseases |
| title_full_unstemmed | Cellular therapies in rheumatic and musculoskeletal diseases |
| title_short | Cellular therapies in rheumatic and musculoskeletal diseases |
| title_sort | cellular therapies in rheumatic and musculoskeletal diseases |
| topic | Adoptive immunotherapy Chimeric antigen receptor Cell- and tissue-based therapy Autoimmune disease Rheumatic and musculoskeletal disease |
| url | http://www.sciencedirect.com/science/article/pii/S2589909024000340 |
| work_keys_str_mv | AT pedrofrancofuquen cellulartherapiesinrheumaticandmusculoskeletaldiseases AT juanafigueroaaguirre cellulartherapiesinrheumaticandmusculoskeletaldiseases AT davidamartinez cellulartherapiesinrheumaticandmusculoskeletaldiseases AT eiderfmorenocortes cellulartherapiesinrheumaticandmusculoskeletaldiseases AT juanegarciarobledo cellulartherapiesinrheumaticandmusculoskeletaldiseases AT fabiovargascely cellulartherapiesinrheumaticandmusculoskeletaldiseases AT danielaacastromartinez cellulartherapiesinrheumaticandmusculoskeletaldiseases AT mustafaalmaini cellulartherapiesinrheumaticandmusculoskeletaldiseases AT januarioecastro cellulartherapiesinrheumaticandmusculoskeletaldiseases |